GALT — GALECTIN THERAPEUTICS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1133416 ·
Last close
$2.91
Market Cap
$293.47M
52W High
$7.13
52W Low
$2.03
ADV30
200,870
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -3,367,000 -3,531,000 13,009,000 11,706,000 46,448,000
Jun 2026 0 — -3,982,000 -9,113,000 14,826,000 13,269,000 151,678,000
Mar 2026 0 — -4,077,000 -5,046,000 15,759,000 14,111,000 145,996,000
Dec 2025 0 — -3,365,000 -5,500,000 19,532,000 17,720,000 145,727,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,889,000
Investing CF
—
Financing CF
$15,387,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.47
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-446,788,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-20,092,000
Pretax Income TTM
$-27,843,000
Interest Exp TTM
$7,751,000
Analysts
1

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -20,085,000 -30,836,000 19,532,000 145,727,000 -126,195,000 -23,875,000
Dec 2024 0 -42,433,000 -47,047,000 17,495,000 120,565,000 -103,070,000 -41,767,000
Dec 2023 0 -38,072,000 -41,066,000 28,200,000 88,441,000 -60,241,000 -32,965,000
Dec 2022 0 -38,352,000 -38,776,000 21,285,000 53,479,000 -32,194,000 -31,056,000

TTM Snapshot

Revenues TTM
$129,000
NetIncome TTM
$-27,843,000
OpCashFlow TTM
—
Assets (Latest)
$14,826,000
Forward EPS
$-1.68

Max Pain — expiry 2028-01-21

max pain strike: $5.00 · spot: $2.98 · call oi: 1,441 · put oi: 2,816
Expected Move to 2028-01-21: ±$3.08 (103.19%) — implied range $-0.10 – $6.05 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
EVMN Evommune, Inc. $290.28M $7.02 —
ALT Altimmune, Inc. $297.72M $1.53 —
EBS Emergent BioSolutions Inc. $288.44M $5.61 —
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —
FULC Fulcrum Therapeutics, Inc. $286.43M $3.75 —

News headlines (Yahoo Finance, 1h cache)

All You Need to Know About Galectin Therapeutics (GALT) Rating Upgrade to Buy
2026-11-18 16:00 · Yahoo
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
2026-11-16 13:00 · Yahoo
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
2026-11-05 13:00 · Yahoo
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
2026-10-06 12:00 · Yahoo
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 12:00 · Yahoo
Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
2026-08-24 14:31 · Yahoo
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
2026-08-14 12:00 · Yahoo
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
2026-08-04 12:00 · Yahoo
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
2026-06-23 12:00 · Yahoo
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
2026-03-31 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.